Overview

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Status:
Completed

Trial end date:
2019-10-09

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection fraction (LVEF > 40%). Secondary objectives are to assess Patient-Reported Outcome (PRO)

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Eli Lilly and Company

Treatments:

Empagliflozin